Advertisement


Ronald de Wit, MD, PhD, on Bladder Cancer: Results From KEYNOTE-057

ESMO 2018 Congress

Advertisement

Ronald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses phase II findings on the efficacy of pembrolizumab in Bacillus Calmette Geurin–unresponsive bladder cancer with high risk for disease progression.



Related Videos

Breast Cancer

Matthew J. Ellis, MB, BChir, PhD, on Breast Cancer: Neoadjuvant Endocrine Therapy

Matthew J. Ellis, MB, BChir, PhD, of the Baylor College of Medicine, discusses data on endocrine therapy alone or in combination with targeted treatments for postmenopausal women w...

Lung Cancer
Immunotherapy

Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy and Targeted Treatments

Johan F. Vansteenkiste, MD, PhD, of Catholic University Leuven, summarizes a session he co-chaired that included discussion of translating advances in stage IV disease to nonmetast...

Kidney Cancer
Immunotherapy

Laurence Albiges, MD, PhD, on RCC: Challenging Established Front-Line Treatment

Laurence Albiges, MD, PhD, of Gustave Roussy, discusses data from the global, phase III JAVELIN trial that compared axitinib plus avelumab vs sunitinib, which could lead to a new s...

Issues in Oncology

Matti S. Aapro, MD, on Advanced Disease: Reducing Use of Futile Treatments

Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the challenges of avoiding futile treatments and the need to work with patients, integrate palliative care, and m...

Skin Cancer

Alexander M.M. Eggermont, MD, PhD, on Melanoma: Advances in Adjuvant Therapy

Alexander M.M. Eggermont, MD, PhD, of Gustave Roussy, discusses findings from recent adjuvant trials in high-risk melanoma, and what the NCCN Guidelines recommend in light of such data as res...

Advertisement

Advertisement



;
Advertisement